Cytomegalovirus (CMV) disease is a common and serious complication of allogeneic stem cell transplantation (SCT). Its two most frequent manifestations are interstitial pneumonitis and gastroenteritis. We describe here the first reported case of CMV ovarian infection in an allo-SCT recipient. This patient was included in a clinical trial of high-dose chemotherapy (HDCT) with HLA-matched peripheral SCT for metastatic breast cancer. She expired 53 days after transplantation from organ failure unrelated to her CMV oophoritis. Keywords: breast cancer; cytomegalovirus; oophoritis; allogeneic stem cell transplant
A 50-year-old postmenopausal female with metastatic breast cancer agreed to participate in an experimental clinical trial of HDCT with allogeneic peripheral SCT from an HLA-identical sibling. Pretreatment organ function was normal. Both patient and donor were CMV-seropositive. The conditioning regimen consisted of busulfan (16 mg/kg p.o.) and melphalan (140 mg/m 2 i.v.). Busulfan was prospectively dose-adjusted, and its final area under the curve remained within the target range. Standard antimicrobial, GVHD prophylaxis and weekly CMV surveillance cultures were performed.
The patient presented with febrile neutropenia and was treated with ceftazidime, vancomycin and amphotericin-B. Neutrophils engrafted on day +12. On day +18 she developed acute respiratory distress, that required intubation. No infectious etiology was found from culture of the bronchoalveolar lavage (BAL). Bilirubin gradually rose to 1248 mol/l (73 mg/dl) on day +41. A transjugular liver biopsy showed cholestasis and hydropic degeneration, but no evidence of GVHD or VOD. Abdominal ultrasoundDoppler showed normal liver parenchyma echogenicity, no CMV shell-vial culture in the BAL on day +35 was negative. Two consecutive CMV blood surveillance cultures were positive by PCR, and ganciclovir was initiated. Blood CMV PCR became negative on two subsequent determinations, 1 and 2 weeks later. No other positive microbiological findings were reported. On day +58 she expired of multiorgan failure.
Postmortem examination showed bilateral diffuse alveolar damage. No viral inclusions were seen and CMV immunostains of the lung were negative. Liver architecture was normal with mild hepatocyte ballonization and intrahepatic canalicular cholestasis. The bone marrow showed partial engraftment with areas of fibrosis and residual tumor manifesting as cytokeratin positive signet ring cells. Ovaries were macroscopically normal. Microscopic examination showed diffuse parenchymal necrosis and cells with abundant cytoplasm and a perinuclear halo, positive for CMV by immunohistochemistry (012D monoclonal antibody to CMV (Biomeda, Foster City, CA, USA) ( Figure 1 ). No additional organs were involved by CMV infection. A retrospective review of the pelvic US examination failed to show any changes in the ovaries. 
Discussion
CMV disease, particularly pneumonitis or gastroenteritis, is a serious complication of allogeneic BMT. The epidemiology of CMV disease in this setting has shifted from CMV-seronegative recipients of seronegative donor marrow to seropositive donor/recipient pairs, probably as a result of the use of leukodepleted blood products. Ganciclovir, either as preemptive therapy 1 or as universal prophylaxis in all CMV seropositive donor/recipient pairs, 2 has reduced the incidence of CMV infection from 70% to less than 10%. In the case reported here, CMV oophoritis, with positive immunohistochemistry for this virus and microscopic evidence of parenchymal destruction, was an incidental finding and unrelated to the patient's death. Since no methods to assess viability of the virus were performed, such as culture or RT-PCR for CMV mRNA, the detection of CMV in this case might not represent active replicating virus.
To the authors' knowledge, CMV oophoritis has not been reported to date in allogeneic stem cell recipients. Autopsy series in the literature seeking CMV infection in allo-SCT have not found oophoritis as a manifestation of CMV disease. [3] [4] [5] In the autopsy of an autologous BMT patient who died of candidal sepsis, CMV was incidentally identified in the ovaries. 6 The incidence of CMV oophoritis in non-BMT autopsy series varies widely, 7, 8 which may reflect inadequate sampling of normal-sized ovaries in women dying of nongynecologic diseases. The histologic findings of CMV oophoritis include cortical necrosis with typical intranuclear and cytoplasmic inclusion bodies and varying inflammatory reaction. 8, 9 It has been hypothesized that the cortical stromal atrophy and accompanying restrictive vascular changes in the postmenopausal ovary may trigger a reactivation of latent CMV in cortical stromal cells. 8 Blood and ovarian levels of ganciclovir were not measured in this patient. It is, therefore, possible that the drug may have reached levels in the ovaries that were sufficient to inhibit CMV replication. However, after 2 weeks of antiviral therapy, CMV PCR and cultures in blood turned negative, whereas the ovaries remained massively infected with CMV with diffuse parenchymal destruction at the postmortem exam. This apparently differing response to ganciclovir raises concern about a potential local factor within the ovaries that may have induced resistance to ganciclovir. Luzi et al 10 performed a doppler ultrasound study of the uterine arteries, and showed greatly decreased ovarian artery blood flow and increased pulse index due to intraovarian vascular resistance in postmenopausal compared with ovulating women. 10 We postulate that such dramatic reduction in blood flow in the postmenopausal ovary may significantly reduce ovarian tissue levels of ganciclovir and serve to sequester CMV from antiviral treatments, so that oophoritis remains untreated despite adequate systemic levels of ganciclovir. Menopause-related cortical vascular deficiency, a putative localizing factor for CMV reactivation, could be further favored by sustained hemodynamic instability caused by the patient's critical condition. These circumstances could turn the ovary into a sanctuary for CMV.
Whether an ovarian reactivation of CMV is merely a terminal event, or could be a potential source of widespread viremia remains unclear.
